The intraperitoneal (i.p.) administration of cisplatin (CDDP) is one of the most effective therapies for cancers that are confined to the abdominal cavity. However, the effect of fluid osmolarity on the therapeutic efficacy of i.p. administration of CDDP has not been well established. In the current study, hypotonic (154 mosmol 1-l), isotonic (308 mosmol 1-l) and hypertonic (616 mosmol 1-l) solutions of CDDP were prepared for an evaluation of their therapeutic efficacy in an experimental system. After i.p. administration, uptake of CDDP in vivo by tumour cells in hypotonic solution was significantly greater than in isotonic or hypertonic solution. The 50% lethal dose (LD50) value of CDDP in hypotonic solution (12.1 mg kg-') was lower than that in isotonic solution (16.9 mg kg-') and than that in hypertonic solution (28.6 mg kg-1). However, when a dose equal to one-half of the LD50 was administered in each solution to mice with i.p. tumours, survival of mice given the CDDP in hypotonic solution was significantly prolonged as compared with the survival of the other mice. These results demonstrate that the therapeutic efficacy of i.p. CDDP in mice is augmented when the drug is administered in hypotonic solution.
Intraperitoneal (i.p.) chemotherapy has been used for adjuvant post-surgical or palliative treatment of ovarian and gastrointestinal malignancies (Cunliffe and Sugarbaker, 1989; McVie, 1990) . The peritoneal cavity is a common site of tumour recurrence after initial 'radical' surgical treatment. Intraperitoneal dissemination of cancer is often widespread but it tends to be confined to the peritoneal cavity. For this reason, i.p. chemotherapy is anatomically appropriate for malignancies within the peritoneal cavity. The major attraction of i.p. chemotherapy is that the peritoneal cavity can be exposed to higher concentrations of the drug than the rest of the body, and the accumulation of the drug in peritoneal tumours is higher than can be easily achieved by i.v. administration (Los et al., 1989) .
Cisplatin (CDDP) is one of the most useful drugs for i.p. chemotherapy (Tsujitani et al., 1993) , but CDDP penetrates to a distance of only 1-3 mm beneath the surface of peritoneal tumour nodules, in spite of its high ability to penetrate tumours (Los and McVie, 1990) . Thus, the therapeutic effect of this drug is confined exclusively to microscopic or small-volume residual tumours. (Los & McVie, 1990; Markman et al., 1993) .
The increased accumulation in tumour cells and the enhanced cytotoxicity of CDDP in hypotonic solution have been confirmed in vitro (Smith and Brock, 1989; Groose et al., 1986) . However, the effects of fluid osmolarity on the accumulation and cytotoxicity have not yet been examined under i.p. conditions, and the effects of osmolarity on the therapeutic efficacy of i.p. CDDP remains to be established.
In the current study, we attempted to clarify the effect of fluid osmolarity on i.p. CDDP chemotherapy. We compared the uptake of CDDP by tumour cells, acute toxicity in mice and rats, and the therapeutic effect of CDDP in tumourbearing mice between solutions of CDDP with different osmolarities. Finney (1952) .
Materials
The pharmacokinetics and toxicity of CDDP were analysed in tumour-free Donryu rats. Rats were given an i.p. injection of CDDP (3 mg kg-') in each solution of sodium chloride. The volume of solution was 100 ml kg-' body weight (CDDP, 30 ,ug ml-'). Six rats per group were sacrificed 5, 15, 30, 60, 180 and 480 min after the i.p. injection of CDDP, for collection of plasma and peritoneal fluid and determinations of levels of both free and proteinbound platinum. Some of each sample of plasma and peritoneal fluid was passed through an ultrafiltration membrane (Centrifree MPS-3, Amicon, Beverly, MA, USA) with centrifugation 1500 g for separation of free platinum from total platinum (Whitlam and Brown, 1981) . Body weight and plasma levels of blood urea nitrogen (BUN) and creatinine were examained 3 and 5 days after injection of CDDP using another six rats from each group.
Study of therapeutic efficacy
Six-week-old male ddy mice were inoculated i.p. with EAT cells (2 x 106). Twenty-four hours and 4 days after inoculation, CDDP (5 mg kg-') in each of the three solutions of sodium chloride was administered i.p. in a volume of 0.1 ml g-' body weight to mice in three groups (ten mice per group). In addition, 4 days after inoculation, CDDP (at half of LD50) in each of the three solutions of sodium chloride was administered in the same manner to three further groups (ten mice per group). In the latter experiment, the dose of CDDP (half of LD_O) did not affect the survival of tumour-free mice. All mice were monitored until death or for 60 days to determine survival time. (1977) . In brief, cell pellets were digested by heating with 60% nitric acid and then the mixture was evaporated to dryness. Each sample was dissolved in 0.1 N nitric acid and platinum was quantitated by flameless atomic absorption spectrophotometry (polarised Zeeman atomic absorption spectrophotometer 180-80; Hitachi, Tokyo, Japan). The intracellular accumulation of platinum was normalised with respect to the cellular protein content, which was determined by the method of Lowry et al. (1951) .
For the determination of total and free platinum in the plasma and peritoneal fluid, each sample was dissolved in 0.1 N nitric acid and platinum was quantitated in the same manner as described above. increase vs e.
